« All Hot Topics

The location of the primary tumour: Impact on outcomes with 1st line Vectibix®

An exploratory analysis of data from the 1st line PRIME and PEAK studies was presented at the ESMO 2016 congress in Copenhagen, which considered the impact of tumour location on outcomes.1

  • In patients with left-sided primary tumours from PEAK, the median overall survival (OS) with Vectibix® + FOLFOX was 43.4 months, nearly 1 year (11.4 months) longer than the median OS with bevacizumab + FOLFOX.1 This adds to the existing four retrospective subgroup analyses showing that Vectibix® with either FOLFOX or FOLFIRI can achieve median OS ≥40 months2–5
  • In 1st line treatment, Vectibix® + FOLFOX showed increased response rates vs chemotherapy with or without bevacizumab in both left-sided and right-sided primary tumours1
    • Further analysis is required to determine the optimal treatment for patients with right-sided primary tumours

Website assets V1a

Adapted from Boeckx et al.1

These analyses further support previous studies showing that tumour sidedness is prognostic, and that patients with left-sided primary tumours fare better than those with right-sided primary tumours.1,6–9

This hot topic describes the findings of this analysis in greater detail,1 and considers their implications.

Left-sided primary tumoursRight-sided primary tumoursTumour sidedness and prognosis

References

  1. Boeckx N, et al. Poster presented at the 2016 Congress of the European Society for Medical Oncology; Copenhagen, Denmark; 7–11 October 2016. Poster 89P.
  2. Peeters M et al. Eur J Cancer 2013;49(suppl 4):abstract MC13–0024 (and poster).
  3. Peeters M et al. Eur J Cancer 2013;49(suppl 4):abstract MC13–0022 (and poster).
  4. Abad A et al. Ann Oncol 2014;25(suppl 4):iv189 (poster 551P).
  5. Schwartzberg L, et al. J Clin Oncol 2014;3221):2240–2247.
  6. Hansen IO, Jess P. Dan Med J 2012;59:A4444.
  7. Loupakis F, et al. J Natl Cancer Inst 2015;107:dju427.
  8. Wang F, et al. Chin J Cancer 2015;34:384–393.
  9. Venook AP, et al. J Clin Oncol 2016;34(suppl):abstract 3504.
-->